G-Protein Coupled Receptors Market Size, Share, Trend Analysis, Segmentation And Forecast To 2033

The g-protein coupled receptors market size has grown strongly in recent years. It will grow from $2.97 billion in 2023 to $3.18 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to drug discovery advances, fda approvals, genomic discoveries, emerging markets, market consolidation, growing aging population.

The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine, increased focus on rare diseases, artificial intelligence in drug discovery, patient-centric drug development, environmental and social factors, biosimilar market growth. Major trends in the forecast period include biotechnology advancements, increased r&d investment, technological innovations, collaborations and partnerships, digital therapeutics.

Market Overview -
G-protein coupled receptors refer to a kind of membrane receptor also known as seven-(pass)-transmembrane receptors. These are present in the cell membrane and are in charge of binding extracellular chemicals and sending signals from these substances to an intracellular molecule. GPCRs are the largest family of membrane proteins and mediate most cellular responses to hormones and neurotransmitters, and being responsible for vision, olfaction, and taste.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11976&type=smp

G-Protein-Coupled Receptors Market Poised For Growth Driven By Escalating Cancer Prevalence
The rising prevalence of cancer is expected to propel the growth of the G-protein-coupled receptors market going forward. Cancer is an illness in which abnormal cells can infect surrounding tissues and spread uncontrollably. The lymphatic and vascular systems of the body are further routes by which cancer cells might spread. GPCRs control the processes identified as the defining characteristics of cancer, including proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and the activation of invasion and metastasis. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization working for cancer care, in the United States, kidney cancer will be discovered in 81,800 individuals in 2023 (52,360 males and 29,440 women. Furthermore, in April 2022, Breast cancer surpassed lung cancer to become the most commonly diagnosed cancer worldwide, affecting an estimated 2.3 million women in 2021 alone, according to the Breast Cancer Research Foundation, a US-based not-for-profit organization in breast cancer for clinical and translational research. In the United States, where breast cancer has been the most frequent cancer for many years, 281,550 women are expected to be diagnosed in 2021 Therefore, the rising prevalence of cancer is driving the growth of the G-protein coupled receptors market.

Competitive Landscape -
Major companies operating in the g-protein coupled receptors market report are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Danaher Corporation, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Thermo Fisher Scientific Inc., Perkin Elmer Inc., Qiagen N.V., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Escient Pharmaceuticals Inc., Structure Therapeutics, Septerna

Lifearc Ventures Backs Maxion Therapeutics And Septerna Inc. To Propel G-Protein-Coupled Receptor Research
Investment to advance GPCR screening and antibody development is a key trend gaining popularity in the G-protein-coupled receptor (GPCR) market. Major companies operating in GPCR are focusing on attaining investment for developing drugs and medication technologies related to GPCR-driven diseases. For instance, in February 2023, LifeArc Ventures, a UK-based venture capital firm, invested $16 million in Maxion Therapeutics, a UK-based drug discovery company, to advance antibody development for previously untreatable ion channel and GPCR-driven disorders. This funding will enable the development of antibody therapeutics targeting ion channels and G-protein-coupled receptors (GPCRs) using the proprietary KnotBody technology. The KnotBody platform enables the discovery of biologicals against ion channels and GPCRs, using naturally occurring cysteine-rich mini proteins. Moreover, Septerna Inc., a US-based biotechnology company, announced its launch and Series A financing of $100 million. This Series A funding will be used for developing its emerging pipeline of innovative GPCR-targeted medication programs powered by the Native Complex Platform and covering numerous therapeutic areas.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report

Key Segments -
The g-protein coupled receptors market covered in this report is segmented -
1) By Product: Cell Lines, Detection Kits, Cell Culture Reagents, Ligands
2) By Assay: CAMP Functional Assays, Calcium Functional Assays, ß-Arrestin Functional Assays, Radioligand Binding and GTP?S Functional Assays, Internalization Assays, Trafficking Assays
3) By Applications: Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Inflammation Research, Respiratory Research, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.